TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

Launched by DUKE UNIVERSITY · Sep 26, 2017

Keywords

ClinConnect Summary

* This study will be a randomized, unblinded, two-arm, multi-center clinical trial of patients with heart failure who are hospitalized. Heart failure need not be the reason for hospitalization. Patients will be randomized 1:1 to either oral torsemide OR oral furosemide prior to hospital discharge. Oral dosing of torsemide compared to furosemide will be 1mg:2mg. The specific loop diuretic dose will be at the discretion of the treating physician with the above noted conversion.
* Trial enrollment occurs before hospital discharge, at the discretion of the healthcare provider.
* As appropriate,...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Patient hospitalized (≥ 24 hours or over a change in calendar date) with worsening of chronic heart failure, or new diagnosis of heart failure AND meets one of the following criteria:
• • 1. Has a left ventricular ejection fraction (EF) ≤40% within 24 months prior to and including index hospitalization by any method (with most recent value used to determine eligibility)
• • 2. Has an elevated natriuretic peptide level (either NT-pro-B-type natriuretic peptide or B-type natriuretic peptide) during index hospitalization as measured by local laboratory (with most recent value used to determine eligibility)
• • 2. Plan for a daily outpatient oral loop diuretic regimen upon hospital discharge with anticipated need for long-term loop diuretic use
• • 3. ≥ 18 years of age
• • 4. Signed informed consent
• Exclusion Criteria:
• • 1. End-stage renal disease requiring renal replacement therapy
• • 2. Inability or unwillingness to comply with the study requirements
• • 3. History of heart transplant or actively listed for heart transplant
• • 4. Implanted left ventricular assist device or implant anticipated \<3 months
• • 5. Pregnant or nursing women
• • 6. Malignancy or other non-cardiac condition limiting life expectancy to \<12 months
• • 7. Known hypersensitivity to furosemide, torsemide, or related agents